Page last updated: 2024-10-22

theophylline and Secondary Hyperparathyroidism

theophylline has been researched along with Secondary Hyperparathyroidism in 1 studies

Research Excerpts

ExcerptRelevanceReference
" Therefore, a clinical drug-drug interaction (DDI) study to evaluate the effects of evocalcet on the pharmacokinetics (PKs) of probe substrates for CYP isozymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP3A) was conducted in healthy male volunteers using a novel cocktail combination."2.90Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. ( Akizawa, T; Endo, Y; Fukagawa, M; Kannami, A; Maeda, H; Nagata, Y; Nakamura, H; Narushima, K; Ohtsuka, S; Shimazaki, R; Shiramoto, M; Uchimura, T, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Narushima, K1
Maeda, H1
Shiramoto, M1
Endo, Y1
Ohtsuka, S1
Nakamura, H1
Nagata, Y1
Uchimura, T1
Kannami, A1
Shimazaki, R1
Fukagawa, M1
Akizawa, T1

Trials

1 trial available for theophylline and Secondary Hyperparathyroidism

ArticleYear
Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.
    Clinical and translational science, 2019, Volume: 12, Issue:1

    Topics: Administration, Oral; Adult; Alkynes; Benzoxazines; Calcimimetic Agents; Carbamates; Cells, Cultured

2019